Assessing Jet Administration of pBI-11 for the Treatment of Patients With HPV16/18+

HPV Infection Clinical Trial

Official title:

Double-Blind Randomized Phase II Clinical Trial Assessing Jet Administration of pBI-11 for the Treatment of Patients With HPV16/18+

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06210854
• Other study ID #: CRMS-83553
• Secondary ID: IRB00408026
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: May 2024
• Est. completion date: July 2026

Study information

• Verified date: April 2024
• Source: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Contact: Kimberly Levinson, MD
• Phone: 410-955-8240
• Email: klevins1[@]jhmi.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized phase II study. The primary goal of this study is to determine the safety and tolerability of three monthly pBI-11 DNA administrations in each thigh of patients with persistent human papillomavirus 16 (HPV16) and/or human papillomavirus (HPV18+).

Description:

This is a randomized phase II study. The primary goal of this study is two-fold; one is to determine the safety and tolerability of three monthly pBI-11 DNA administrations in each thigh of patients with persistent HPV16 and/or HPV18+ < cervical intraepithelial neoplasia 2 (CIN2), wherein either 0.1 mL (0.3 mg) of the plasmid DNA is administered intradermally (I.D.) into each thigh (for a total of 0.6 mg DNA at each visit) using a Pharmajet Tropis device, or 0.5 mL (1.5 mg) of the plasmid DNA is administered intramuscularly (I.M.) into each thigh (for a total of 3 mg DNA at each visit) using a Pharmajet Stratis device; and the other is to evaluate the effect of vaccine on (HPV16/18) viral DNA clearance. Secondary goals are to seek preliminary evidence of prevention of disease progression and assess induction of an HPV16/18-specific immune response to select the appropriate regimen for a subsequent phase III clinical trial. Persistence is defined as positivity on two sequential tests. A total of 72 participants will be enrolled in 4 arms of the study in a 2:1:2:1 ratio (24 patients randomized to the intervention and 12 patient randomized to placebo via Tropis device, and 24 patients randomized to the intervention and 12 patient randomized to placebo via Stratis device).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 72
• Est. completion date: July 2026
• Est. primary completion date: January 2026
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients must have:

Negative for Intraepithelial Lesions (NEIL), Atypical Squamous Cells of Undetermined Significance (ASC-US), or Low-grade Squamous Intraepithelial Lesion (LSIL) determined by cervical cytology AND HPV16 and/or 18+ by Roche Cobas 4800, Roche Linear Array HPV Genotyping test, or other FDA-approved HPV genotyping test (Co-infections with HPV types other than HPV16/18 are permissible).

2. Age = 18 years

3. Baseline Eastern Cooperative Oncology Group performance status of 0, 1 at the time of treatment administration.

4. Patients must have adequate organ function at the time of enrollment as defined by the

following parameters:

• White blood cell count = 3,000
• Absolute lymphocyte number = 500
• Absolute neutrophil count = 1,500
• Platelets = 90,000
• Hemoglobulin = 9
• Total bilirubin < 3 X the institutional limit of normal
• Aspartate Aminotransferase (AST)/Alanine Aminotransferase(ALT) < 3 X the institutional limit of normal
• Creatinine < 2.5 X the institutional limit of normal

5. Women of child-bearing potential must agree to use long acting contraception (e.g. tubal ligation, intrauterine devine or hormonal implant) or two forms of contraception (e.g. barrier method, oral contraceptives) prior to study entry and for 3 months after final vaccination.

6. Ability to understand and the willingness to sign a written informed consent document.

7. Subject is able to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

1. Histologic evidence of CIN2, cervical intraepithelial neoplasia 3 (CIN3), adenocarcinoma in situ or malignancy.

2. Patients with a diagnosis of immunosuppression or active systemic use of immunosuppressive medications such as steroids.

3. Patients who are receiving any other investigational agents within 28 days prior to the first dose.

4. Patients with an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

5. Patients with a history of systemic autoimmune disease such as multiple sclerosis or systemic lupus erythematosus (SLE), but exclusive of a history of thyroiditis, psoriasis, Sjrogen's, or inflammatory bowel disease.

6. Patients who are pregnant or breast feeding or plan to become pregnant within five months of first study treatment.

7. Patient with active infection of, or receiving treatment for Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), or Hepatitis B Virus (HBV).

8. History of prior malignancy with disease free interval <5 years; however, individuals with completely resected basal cell or squamous cell carcinoma of the skin within this interval may be enrolled.

Related Conditions & MeSH terms

• HPV Infection
• Papillomavirus Infections

Intervention

Drug:
• pBI-11
HPV16/18 vaccine

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of Vaccination	To determine the safety of repeat administration of pBI-11 DNA vaccine in patients with persistent HPV16/18+	12 months
Primary	Feasibility of Vaccination	To determine the feasibility of repeat administration of pBI-11 DNA vaccine in patients with persistent HPV16/18+	12 months
Primary	Effect of Vaccination	To assess the effect of pBI-11 vaccination on the clearance of HPV16/18 in cytologic specimens at month 6	6 months
Secondary	Impact of Vaccination on Progression to HPV 16/18	To assess the impact of vaccination upon progression to HPV16/18 messenger RNA (mRNA)+ CIN2+ by month 12	12 months
Secondary	Levels of HPV16/18	To evaluate the levels and phenotype of circulation HPV16/18 E6/E7-specific T cells in peripheral blood pre- and post-vaccination by each regimen	Baseline, 6 months, and 12 months
Secondary	Changes in Cytopathology	To evaluate changes in cytopathology of specimens taken pre- and post-vaccination by each regimen	Baseline, 6 months, and 12 months